Kornimate/medical-research-clean huggingface dataset:
suppressive antibacterial therapy with once-weekly secnidazole granules to prevent recurrent bacterial vaginosis; a pilot study

Conditions: Recurrent Bacterial Vaginosis

Summary: the purpose of this study is to test the effectiveness secnidazole to treat recurrent bv. secnidazole is approved for one-time use in acute bv. in this study, the drug will be used for recurrent bv, and given weekly for 18 weeks.

a single-center prospective pilot study with once-weekly oral secnidazole granule treatment of acute condition for two-weeks followed by prophylactic treatment of asymptomatic responders with once-weekly secnidazole for 16 weeks, followed by no therapy for 12 weeks. the final follow-up evaluation is at week 28. eligible women with a current symptomatic bacterial vaginosis infection (\> or = 3 amsel criteria) and a history of at least 2 previous episodes of bacterial vaginosis in the past year will be enrolled in the open-label treatment study. all women will be treated with 2g of secnidazole granules orally once-weekly for 2 weeks. at the second visit, 3-5 days after completion of treatment, women who have a resolution of bacterial vaginosis (asymptomatic and \< or = 2 amsel criteria) will continue on once-weekly secnidazole for 16 weeks. patients will be evaluated every 4 weeks for recurrence of bacterial vaginosis. this will include questions about symptoms as well as a pelvic examination for assessment of vaginal discharge (\> or = 3 amsel criteria). we will also collect any information on other clinical evaluations for recurrence and the dates of diagnoses and types of treatments they may have received. those who remain without recurrence during the 16-week suppressive phase will be followed for an additional 12 weeks off therapy, with assessment for recurrence at weeks 22 and 30. throughout the study, data will be collected on participants' compliance and on the occurrence of adverse events.

Eligibility criteria:
inclusion criteria: * ability to consent in english * current symptomatic bacterial vaginosis infection * history of at least 2 previous episodes of bacterial vaginosis in the past year exclusion criteria: * current gynecologic infection or condition, including candida vaginitis, gonorrhea, chlamydia, trichomonas, desquamative inflammatory vaginitis, atrophic vaginitis. * pre-existing heart conditions * pre-existing neurological conditions * currently pregnant or breastfeeding * women taking anticoagulants, lithium, metoclopramide, or disulfiram therapy * hypersensitivity to secnidazole or other drugs in the same class.
ono-4538 study in patients with richter's transformation

Conditions: Richter's Transformation

Summary: investigate the efficacy and safety of ono-4538 in patients with richter's transformation


Eligibility criteria:
inclusion criteria: * diagnosis of diffuse large b-cell lymphoma (dlbcl)-type or hodgkin lymphoma (hl)-type richter's transformation * in the case of dlbcl-type richter's transformation, refractory, intolerant or ineligible for treatment of dlbcl * patients with measurable disease * eastern cooperative oncology group (ecog) performance status of 0 or 1 * expected to survive for 90 days or more exclusion criteria: * serious complications * active multiple cancers * active central nervous system (cns) disease * history of allogeneic hematopoietic stem cell transplantation
autologous stem cells transplantation in patients with idiopathic and drug induced premature ovarian failure

Conditions: Premature Ovarian Failure

Summary: premature ovarian failure (pof), also known as premature ovarian insufficiency, primary ovarian insufficiency (this is the most accurate term as some women may still conceive), premature menopause, hypergonadotropic hypogonadism is defined as failure of the ovary to function adequately in a woman younger than 40 years, in its role either as an endocrine organ or as a reproductive organ, a condition characterized by amenorrhea, hypoestrogenism, and elevated serum gonadotropin levels (which demonstrate that the ovaries are no longer responding to circulating fsh by producing estrogen and developing fertile eggs) in women younger than 40 years. this condition occurs in approximately 1% of women and it has important physical and psychological consequences/impact in those patients. the purpose of this study is to investigate the role of the transplantation of bone marrow derived stem cells into ovarian tissue for treatment of premature ovarian failure and to assess their ability to differentiate into germ cells.

this study is an open-label investigation of the efficacy of injection of autologous adult bone marrow derived stem cells into the ovarian stroma of patients with premature ovarian failure. sixty women with premature ovarian failure will be recruited in this study after a written informed consent. diagnosis will be based mainly on history taking, physical examination and investigations. laboratory investigations will include serum follicle-stimulating hormone (fsh), serum estrogen measurement and serum amh. the anterior pituitary secretes fsh and lh at high levels due to the dysfunction of the ovaries and consequent low estrogen levels. typical fsh in pof patients is over 40 mlu/ml (post-menopausal range). subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. human adult bone marrow derived stem cells will be transplanted by a gynecological surgeon through a standard surgical approach (transvaginal u/s guided approach). subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection. for safety of participants, bone marrow stem cells will be injected in one ovary only and the other ovary will be spared.

Eligibility criteria:
inclusion criteria: * patients with normal karyotype spontaneous premature ovarian failure. * patients between 18 - 40 years old. exclusion criteria: * patients with secondary ovarian failure (e.g. hypothalamic causes). * pregnancy and lactation. * autoimmune diseases. * those with major medical problems such as malignancy, hepatitis, etc. * abnormal karyotyping (e.g. turner syndrome, fragile x syndrome....).
covid-19 associated mucormycosis: a multidisciplinary dilemma in assiut university hospital

Conditions: Mucormycosis

Summary: we aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of covid-19. all patients with covid-19 associated mucormycosis (cam) admitted to assuit university hospital between march 1, 2021, and july 30, 2021, were included in this study. the patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with covid-19.


Eligibility criteria:
inclusion criteria:we recruited all cases admitted to assuit university hospital for the management of covid-19 and/or associated complications between march 1, 2021, and july 30, 2021, specifically those with probable mucormycosis based on clinical condition. at various times, internists, intensivists, neurologists, and otolaryngologists were among the specialists who assessed and treated them. clinical; radiological and histopathological confirmed cases of mucormycosis with coexisting or previous history of covid-19 were included in this study. - exclusion criteria:participants with fungal infections other than mucormycosis or without a confirmed diagnosis of covid-19 (or serological evidence of preceding covid-19) were excluded. -
myofascial release in patients with chronic obstructive pulmonary disease

Conditions: Copd

Summary: the main objective of this study is to assess the effects of a myofascial release protocol in patients with chronic obstructive pulmonary disease (copd).

so far, there are no previous studies that analyze the effects of a myofascial relaxation protocol applied to the diaphragm within the respiratory rehabilitation treatment in patients with chronic obstructive pulmonary disease. aim: the main objective of this study is to assess the effects of a 3 weeks myofascial release protocol applied to the diaphragm on respiratory parameters in patients with chronic obstructive pulmonary disease. design: randomized clinical trial

Eligibility criteria:
inclusion criteria: * copd; * forced expiratory volume in the first second (fev1) \< 80%; * fev1/forced vital capacity (fvc) \< 70%; * maximal inspiratory pressure (mip) \< 70%. exclusion criteria: * recent (6 months) spine or abdominal surgery; * allergic status of any kind; * systemic diseases (rheumatic, infectious conditions, febrile state, vascular alterations, endocrine diseases including diabetes, metabolic, and neoplastic syndromes); * neuromuscular or neurological injuries; * previous myofascial release treatment.
changes in motor latency during spinal decompression: relationship to outcomes

Conditions: Spinal Stenosis

Summary: is there a relationship between changes in motor evoked potential latency intraoperatively and post-operative changes in walking function in patients undergoing spinal decompression.

is there a relationship between changes in motor evoked potential latency intraoperatively and post-operative changes in walking function in patients undergoing spinal decompression. tests will include the pre and post decompression mep (motor evoked potential) latency and pre and post surgery walking speed and quality of life assessments.

Eligibility criteria:
inclusion criteria: * central spinal stenosis * ability to ambulate prior to onset of symptoms exclusion criteria: * arthritis affecting walking ability (hip, knee or ankle). * diabetes * implanted pacemaker or other electrostimulator.

Keywords: spinal stenosis motor evoked potential
daas treatment for chronic hcv/hbv co-infection patients(dasco)

Conditions: Chronic Hepatitis C Infection; HBV Coinfection; Hepatitis B Reactivation

Summary: this is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis b virus replication during direct anti-hcv treatment of hcv/hbv co-infection patients.

patients who receive direct-acting anti-hcv treatment will be prospectively studied during 2-year period. all patients have hcv/hbv co-infection. the inclusion/exclusion criteria and the follow up plan will be listed in following part.

Eligibility criteria:
inclusion criteria: * hcv rna positive, * hbsag positive with detectable or undetectable hbv dna, * receiving pan oral direct-acting anti-hcv regimen exclusion criteria: * pregnant or nursing female or male with pregnant female partner; * hiv infection; * hematologic or biochemical parameters at screening outside the protocol- specified requirements; * active or recent history (≤ 1 year) of drug or alcohol abuse; * history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
young men and media study

Conditions: Sexual Behavior

Summary: adolescent sexual minority males (asmm) continue to account for a disproportionate number of hiv infections in the united states. racial and ethnic minority populations are particularly affected. increased hiv rates reflect sexual risk behaviors during early sexual experiences. research suggests that initial sexual risk-taking occurs during adolescence among sexual minority males. therefore, it is important for hiv prevention interventions to target adolescent sexual minority males. targeting sexual minority males during adolescence will help them learn and establish healthy sexual behaviors early in their psychosexual development, which will have both immediate and long-term health benefits.to promote adolescent sexual minority males' critical examination of online media and decrease their sexual risk-taking, this study proposes an exploratory clinical trial to pilot test an online sexual health media literacy intervention that was developed during formative research for feasibility and acceptability. overall, the proposed research has the potential to reach a wide audience of sexual minority males early in their sexual development, ultimately decreasing their sexual risk-taking and reducing the number of new hiv infections in this population.


Eligibility criteria:
inclusion criteria: * self-identify as sexual minority * have intentionally accessed seom * have a valid personal email address * be a us resident * be new to the study exclusion criteria: * are unwilling or unable to provide informed assent * are unable to understand and read english * do not have the appropriate device and necessary software to experience all the intervention content

Keywords: adolescent sexual minority males (asmm) gay, bisexual, and other men who have sex with me (gbmsm) online sexual health media literacy intervention hiv prevention healthy sexual behaviors
high-intensity laser therapy: effectiveness on knee osteoarthritis patients

Conditions: Osteoarthritis, Knee

Summary: the aim of this prospective, randomized, double-blinded study is to investigate the additional benefits of high-intensity laser therapy (hilt) over conventional physiotherapy, related to pain and function, in patients with knee osteoarthritis (koa).

the study was performed in baskent university physical therapy and rehabilitation unit. 43 patients of both sexes, who were diagnosed clinical and radiographic knee osteoarthritis, with kellgren lawrence grade 2 and 3, were randomly assigned in two groups. group 1 (n = 21) received tens, hp, exercises (ex), and high-intensity laser therapy (hilt; nd:yag laser, 10w). group 2 (n = 22) received the same interventions but placebo hilt. all interventions were applied for 10 sessions. the visual analog scale (vas), western ontario \& mcmaster universities osteoarthritis questionnaire (womac), and lequesne algofunctional index (lai) were performed before, after, and at 12-week follow-up.

Eligibility criteria:
inclusion criteria: * both sexes and age between 40 and 65; * pain at least 3 months on single or both knees * diagnosed as koa with kellgren lawrence (kl) grade 2 or 3 koa on weight-bearing anteroposterior x-ray images * normal serum acute phase reactants and uric acid levels * had no major effusion in the joint. exclusion criteria: * therapeutic joint injection in the last 6 months * physical therapy and/or hilt in the last 3 months * any surgical invention for the knee joint * malignancy in the last 5 years.

Keywords: high-intensity laser rehabilitation pain osteoarthritis
efficacy of guided biofilm therapy in pediatric patient

Conditions: Oral Hygiene, Oral Health; Pediatric Pain and Anxiety

Summary: the present parallel randomized clinical trial aims to assess the efficacy of a plaque disclosing agent (pda) and air-flowing with erythritol powder (guided biofilm therapy) in the removal of biofilm and plaque in paediatric participants during professional oral hygiene, compared with ultrasonic debridement. the participants will be divided in four groups and receive: * guided biofilm therapy with plaque disclosing agent (gbt+) * guided biofilm therapy without plaque disclosing agent (gbt-) * ultrasonic debridement and polishing with plaque disclosing agent (us+c+) * ultrasonic debridement and polishing without plaque disclosing agent (us+c-) clinical and image software analysis (imagej) of residual plaque will be performed.

oral biofilm is not easily detectable visually, so its removal can be difficult. using a plaque disclosing agent to highlight biofilm and plaque could aid during its removal and may be beneficial. in paediatric patients, often times it is more difficult to perform professional oral hygiene because of lack of compliance. our hypothesis is that the visual guide of the plaque disclosing might help obtaining a better result in terms of plaque removal. moreover, the use of air-flowing could lead to several advantages compared to traditional professional oral hygiene (ultrasonic debridement and polishing cups), such as increased comfort and compliance, shorter treatment time, easier access to difficult areas and the minimal-invasiveness on soft and hard tissue. the study is a mono-centric, pragmatic, single-blinded, randomized clinical trial (rct) of parallel design. the primary outcome is the residual plaque area (rpa) expressed in percentage of area with residual plaque highlighted by disclosing plaque agent. secondary outcomes are full mouth plaque score (fmps), treatment time and participants' feedback.

Eligibility criteria:
inclusion criteria: * signed informed consent form (pediatric patient and parent). * male and female subjects, aged 6 -12 years, inclusive. * good general health (asa i e ii) * with at least 80% of dentition present * with at least 8/12 frontal dental elements. exclusion criteria: * not willing to follow the agreed protocol. * presence of orthodontic appliances. * tumors or significant pathology of the soft or hard tissues of the oral cavity. * current radiotherapy or chemotherapy. * history of allergy to erythritol. * history of adverse reactions to lactose or fermented milk products.

Keywords: guided biofilm therapy discloser agent airflowing polishing patient feedback
feetme® monitor: alternative for the evaluation of gait speed after stroke

Conditions: Stroke; Gait Disorders, Neurologic

Summary: the aim of this study is to validate a smart insoles system in comparison to the gold-standard gaitrite for a pathologic gait. the device evaluate gait parameters in real time thanks to an embedded algorithm based on the processing of inertial measurement unit and 19 sensors signals. at d0 and d7, the patient is evaluated by both the gaitrite® system and the feetme monitor® system simultaneously. hemiparetic patients have two measurements 7 days apart. the patient repeats 5 trials at a comfortable speed on the gaitrite® mat while wearing the feetme® insoles. each measurement is repeated by 4 different operators. a total of 20 trials are made by the patient.


Eligibility criteria:
inclusion criteria: * have more than 18 years old * don't be pregnant or breast feeding * have a stroke for more than 6 months exclusion criteria: * be part of another study * not be able to give consent * not have access to social security

Keywords: gait analysis stroke feetme gaitrite
comparison of hyalomatrix and integra wound matrix on burn wounds

Conditions: Bandages

Summary: the purpose of this randomized, comparative study is to determine whether hyalomatrix is as effective as integratm meshed bilayer wound matrix when used in subjects who receive concurrent treatments with both products on their first and/or second degree burns located on both hands.


Eligibility criteria:
inclusion criteria: * written consent must be obtained * first and/or second degree burns on both hands * subject must be enrolled within 48 hours of the injury occurrence. exclusion criteria: * subject is breastfeeding, pregnant, or has intentions of becoming pregnant during the course of their study participation. * subject has a prognosis that indicates unlikely survival past the study period. * subject's diagnosis indicates third degree burns. * subject suffers from burns sustained as a result of an electrical/chemical injury or by frostbite. * subject suffers from any inhalation-related burn trauma. * subject suffers from ongoing bone fractures. * subject has a known sensitivity to materials containing silicone, hyaluronan, bovine collagen, or chondroitin and/or derivatives of these products. * subject has received any treatment prior to study enrollment that may, in the opinion of the investigator, affect the outcome of the study. * subject suffers from a medical condition that may impede wound healing, above any beyond that which would typically be expected.
effect of propofol on renal injury in patients undergoing valvular heart surgery

Conditions: Heart Valve Disease

Summary: ischemia/reperfusion (i/r)-induced acute kidney injury is a serious complication affecting patient outcome following cardiovascular surgeries. propofol, an intravenously administered anesthetic with antioxidant properties, protects organs from i/r injury. this study aimed to investigate the ability of propofol to protect kidneys against i/r injury in the patients undergoing valvular heart surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing valvular heart surgery. * age: 20\~75. exclusion criteria: * emergency operation. * patients with vitamin e or vitamin c within 5 days before surgery. * patients with preoperative c-reactive protein (crp) \> 16 mg/l. * patients with serum creatinine ≥ 2.0 mg/dl * patients under hemodialysis. * patients with acute myocardial infarction within 1 week before surgery
reduction of myopotential interference with smart pass in s-icd patients

Conditions: Subcutaneous ICD; Myopotential Interference

Summary: this study is enrolling participants who are already implanted with a s-icd device ( subcutaneous icd), and are undergoing a routine outpatient clinic follow up appointment to have their s-icd checked. the aim of the study is to see if a feature in the device can recognize muscle movement and differentiate movement from irregular heart signals. the study involves doing some simple arm exercises while collecting device data, both with this feature turn on and then with it turned off. participants will be randomized to either have the feature turned on or off initially then it will be programmed the alternative way and the same exercise testing will be repeated. the study will involve just one visit.

this study is enrolling participants who are already implanted with a s-icd device ( subcutaneous icd), and are undergoing a routine outpatient clinic follow up appointment to have their s-icd checked. the aim of the study is to see if a feature in the device can recognize muscle movement and differentiate movement from irregular heart signals. the study involves doing some simple arm exercises while collecting device data, both with this feature turn on and then with it turned off. participants will be randomized to either have the feature turned on or off initially, then it will be programmed the alternative way and the same exercise testing will be repeated. the study will involve just one visit. following this visit study participation is complete.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * implanted emblem s-icd (model a 209 and model a 219, boston scientific, st paul, mn, usa) exclusion criteria: * less than 18 years of age * hemodynamically unstable * inability to preform tet due to orthopedic issues or cognitive impairment

Keywords: device interrogation
outpatient swallowing therapy for subjects with neurological illness

Conditions: Dysphagia

Summary: health care staff in the municipalities do not always have the necessary competencies to treat patients with dysphagia. at the present neurorehabilitation hospital dysphagia examinations for outpatients are provided. the objective is to investigate the effect of a specialized outpatient dysphagia unit for subjects with dysphagia following neurological illness. occupational therapists from the outpatient dysphagia unit will train with subjects for 2-3 weeks, and supervise furter training provided by health care staff in the municipalities.


Eligibility criteria:
inclusion criteria: * neurological illness * living in the region of central jutland * fedss score 2-6 exclusion criteria: -